These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 38518105)
1. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Lenk L; Baccelli I; Laqua A; Heymann J; Reimer C; Dietterle A; Winterberg D; Mary C; Corallo F; Taurelle J; Narbeburu E; Neyton S; Déramé M; Pengam S; Vogiatzi F; Bornhauser B; Bourquin JP; Raffel S; Dovhan V; Schüler T; Escherich G; den Boer ML; Boer JM; Wessels W; Peipp M; Alten J; Antić Ž; Bergmann AK; Schrappe M; Cario G; Brüggemann M; Poirier N; Schewe DM Blood; 2024 Jun; 143(26):2735-2748. PubMed ID: 38518105 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219 [TBL] [Abstract][Full Text] [Related]
3. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia. González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562 [TBL] [Abstract][Full Text] [Related]
4. New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models. Hixon JA; Andrews C; Kashi L; Kohnhorst CL; Senkevitch E; Czarra K; Barata JT; Li W; Schneider JP; Walsh STR; Durum SK Leukemia; 2020 Jan; 34(1):35-49. PubMed ID: 31439943 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain. van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637 [TBL] [Abstract][Full Text] [Related]
6. An Fc-engineered CD19 antibody eradicates MRD in patient-derived Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia. Wang A; Song Z; Zheng G; Nicolazzi C; Fromm JR; Shehu E; Srinivasan S; Chen X; Zhu C; Blondel MC; Adrian FJ Mol Cancer Ther; 2021 Oct; 20(10):1916-1925. PubMed ID: 34376579 [TBL] [Abstract][Full Text] [Related]
8. Growth of human T cell acute lymphoblastic leukemia lymphoblasts in NOD/SCID mouse fetal thymus organ culture. Ma F; Manabe A; Wang D; Ito M; Kikuchi A; Wada M; Ito M; Ohara A; Hosoya R; Asano S; Tsuji K Leukemia; 2002 Aug; 16(8):1541-8. PubMed ID: 12145696 [TBL] [Abstract][Full Text] [Related]
9. Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia. McGinn OJ; Krishnan S; Bourquin JP; Sapra P; Dempsey C; Saha V; Stern PL Haematologica; 2017 Jun; 102(6):1075-1084. PubMed ID: 28341731 [TBL] [Abstract][Full Text] [Related]
10. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279 [TBL] [Abstract][Full Text] [Related]
11. A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. Akkapeddi P; Fragoso R; Hixon JA; Ramalho AS; Oliveira ML; Carvalho T; Gloger A; Matasci M; Corzana F; Durum SK; Neri D; Bernardes GJL; Barata JT Leukemia; 2019 Sep; 33(9):2155-2168. PubMed ID: 30850736 [TBL] [Abstract][Full Text] [Related]
12. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. Müller K; Vogiatzi F; Winterberg D; Rösner T; Lenk L; Bastian L; Gehlert CL; Autenrieb MP; Brüggemann M; Cario G; Schrappe M; Kulozik AE; Eckert C; Bergmann AK; Bornhauser B; Bourquin JP; Valerius T; Peipp M; Kellner C; Schewe DM Blood; 2022 Jul; 140(1):45-57. PubMed ID: 35452517 [TBL] [Abstract][Full Text] [Related]
13. Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia. Vicioso Y; Gram H; Beck R; Asthana A; Zhang K; Wong DP; Letterio J; Parameswaran R Cancer Immunol Res; 2019 Jul; 7(7):1106-1119. PubMed ID: 31138521 [TBL] [Abstract][Full Text] [Related]
14. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399 [TBL] [Abstract][Full Text] [Related]
15. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer. Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402 [TBL] [Abstract][Full Text] [Related]
16. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440 [TBL] [Abstract][Full Text] [Related]
18. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells. Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395 [TBL] [Abstract][Full Text] [Related]
19. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857 [TBL] [Abstract][Full Text] [Related]
20. Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade. Schewe DM; Vogiatzi F; Münnich IA; Zeller T; Windisch R; Wichmann C; Müller K; Bhat H; Felix E; Mougiakakos D; Bruns H; Lenk L; Valerius T; Humpe A; Peipp M; Kellner C Hemasphere; 2024 Feb; 8(2):e48. PubMed ID: 38435424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]